Contacts   Site Map

Search

Neulasta®(pegfilgrastim) Partner: Amgen Indication: Neutropenia Status: Approved in the U.S.

Amgen’s Neulasta® (pegfilgrastim) is approved for the treatment of neutropenia, a condition where the body produces too few white blood cells. Neutropenia can be caused by drugs used to treat cancer during chemotherapy. A low white blood cell count can put some patients at risk for severe infections and interruptions in cancer treatment ^1-3.

Amgen developed Neulasta® using Nektar’s proprietary Advanced PEGylation technology and reagents (a 20 kDa polyethylene glycol (PEG) derivative). This patented PEG technology prolongs the length of time the drug stays in the body, and allows for administration in a single dose per chemotherapy cycle instead of multiple doses per cycle. By keeping the body’s natural defenses strong, Neulasta® helps reduce therisk of a potentially life-threatening infection and/or delay of chemotherapy.

This information should not be used as a source for prescribing information on Neulasta.

References:

1. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med. 1991;325:164-170.
2. Bertini M, Freilone R, Vitolo U, et al. P-VEBEC: a new 8-weekly schedule with or without rG-CSF for elderly patients with aggressive non-Hodgkin’s lymphoma (NHL). Ann Oncol. 1994;5:895-900.
3. de Graaf H, Willemse PHB, Bong SB, et al. Dose intensity of standard adjuvant CSF with granulocyte colony-stimulating factor for premenopausal patients with node-positive breast cancer. Oncology. 1996;53:289-294

Source: www.neulasta.com